Beam Therapeutics Sees Unusually High Options Volume (NASDAQ:BEAM)

Beam Therapeutics Inc. (NASDAQ:BEAM) was the recipient of some unusual options trading activity on Tuesday. Investors bought 2,753 call options on the stock. This represents an increase of approximately 160% compared to the average daily volume of 1,058 call options.

Large investors have recently bought and sold shares of the business. Liberty Wealth Management LLC purchased a new position in Beam Therapeutics during the 3rd quarter valued at about $25,000. Banque Cantonale Vaudoise acquired a new position in Beam Therapeutics during the third quarter valued at approximately $25,000. Meeder Asset Management Inc. acquired a new position in Beam Therapeutics during the third quarter valued at approximately $34,000. Laurel Wealth Advisors LLC acquired a new position in Beam Therapeutics during the fourth quarter valued at approximately $36,000. Finally, Allworth Financial LP lifted its position in Beam Therapeutics by 110.0% during the fourth quarter. Allworth Financial LP now owns 462 shares of the company’s stock valued at $38,000 after buying an additional 242 shares in the last quarter. Hedge funds and other institutional investors own 49.79% of the company’s stock.

NASDAQ:BEAM traded down $9.86 during mid-day trading on Tuesday, hitting $100.55. 74,101 shares of the company’s stock traded hands, compared to its average volume of 1,027,591. The firm’s 50 day simple moving average is $102.66 and its 200 day simple moving average is $67.85. Beam Therapeutics has a 1 year low of $13.00 and a 1 year high of $126.90. The company has a market cap of $5.83 billion and a PE ratio of -6.18.

Several brokerages recently commented on BEAM. Wells Fargo & Company began coverage on shares of Beam Therapeutics in a research note on Tuesday, February 16th. They issued an “overweight” rating and a $145.00 price objective for the company. JPMorgan Chase & Co. cut shares of Beam Therapeutics from an “overweight” rating to a “neutral” rating and raised their price objective for the company from $38.00 to $100.00 in a research note on Friday, January 29th. Finally, Stifel Nicolaus began coverage on shares of Beam Therapeutics in a research note on Tuesday, January 5th. They issued a “hold” rating for the company. One analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. Beam Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $57.14.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders.

Recommended Story: Understanding Options Trading

Receive News & Ratings for Beam Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beam Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.